Newbury Pharmaceuticals AB (OSTO:NEWBRY) EV-to-EBITDA : -4.44 (As of Jun. 04, 2024)

Newbury Pharmaceuticals AB EV-to-EBITDA Chart

Newbury Pharmaceuticals AB Quarterly Data
	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBITDA	Get a 7-Day Free Trial									-5.66	-3.76	-3.83	-3.58	-5.20

Competitive Comparison of Newbury Pharmaceuticals AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newbury Pharmaceuticals AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Newbury Pharmaceuticals AB's EV-to-EBITDA falls into.

Newbury Pharmaceuticals AB EV-to-EBITDA Calculation

Newbury Pharmaceuticals AB's EV-to-EBITDA for today is calculated as:

Newbury Pharmaceuticals AB's current Enterprise Value is kr66.85 Mil.
Newbury Pharmaceuticals AB's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-15.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB  (OSTO:NEWBRY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Newbury Pharmaceuticals AB's PE Ratio for today is calculated as:

Newbury Pharmaceuticals AB's share price for today is kr3.02.
Newbury Pharmaceuticals AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.889.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Newbury Pharmaceuticals AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Newbury Pharmaceuticals AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Business Description